Why Sinovac Biotech, Burlington Stores, and ZIOPHARM Oncology Are Today's 3 Best Stocks

The S&P makes up nearly all of yesterday's lost ground, while Sinovac, Burlington, and ZIOPHARM all rise by double digits.

Mar 20, 2014 at 5:15PM

Mixed, but stabilizing, economic data was the name of the game today that helped push the broad-based S&P 500 (SNPINDEX:^GSPC) higher, practically erasing almost all of yesterday's losses.


As per the norm, we got initial weekly jobless claims data today, which showed a less than 2% increase to a seasonally adjusted 320,000. In a perfect world, we never want to see jobless claims rise, but a figure of 320,000 appears low enough to warrant an ongoing drop in the unemployment rate.

What really seemed to invigorate investors today was a surprising 0.5% jump in leading indicators for February after a tame 0.1% rise in January, and a 0.1% decline in December. This big jump gives investors hope that the U.S economy will rebound voraciously from its early season weather-induced slump.

On the flip side, existing home sales data continues to be weak. February's data showed a decline of 0.4% to a seasonally adjusted annual rate of 4.6 million, matching economists' expectations, but also hitting their lowest levels since July 2012. Although low inventories are helping home prices, the precarious drop in mortgage originations anytime interest rates have even the slightest uptick is concerning.

Despite the mixed data, the S&P 500 pushed higher by 11.24 points (0.60%) to close at 1,872.01.

Topping the charts today was China-based infectious disease vaccine developer Sinovac Biotech (NASDAQ:SVA), which jumped 17.1% after reporting its fourth-quarter results. For the quarter, Sinovac saw sales increase 17%, to $22.9 million, as it reported net income of $0.10 per share compared to a net loss of $0.08 per share in Q4 last year. By comparison, Wall Street was looking for Sinovac to report a loss of $0.01 per share, so this was a sizable beat. While sales of comparable products (e.g., hepatitis and influenza vaccines) actually fell 19% year over year, the addition of an H5N1 vaccine produced $7.2 million in revenue, which helped propel Sinovac higher. It's hard to argue against a company focused on treating infectious diseases given that so many countries around the world still lack access to these basic vaccines, but at 50 times forward earnings, much of that optimism may already be baked into Sinovac's share price.

Sticking with our theme of earnings-driven events, discount branded retail and accessories chain Burlington Stores (NYSE:BURL) gained 15.8% after reporting market-topping profits in the fourth quarter. Profit for the quarter dipped to $1.07 per share from $1.15 in the year-ago quarter, but handily surpassed the $1.03 per share that Wall Street expected. The results, though, were largely mixed, with comparable-store sales growing 4% during the quarter and signaling robust growth; yet, its first-quarter EPS forecast of $0.19-$0.23 in EPS bracketed a bit lower than Wall Street's forecast of $0.23 per share. Overall, I'm a bit put off by Burlington, which is valued at 21 times forward earnings, and is only forecasting same-store sales growth of 2%-3% in the upcoming year. I believe there are considerably more attractive places to put your money to work in the retail sector.

Finally, clinical-stage biopharmaceutical company ZIOPHARM Oncology (NASDAQ:ZIOP) jumped 11.8% following a rating initiation from Mizuho Financial Group. Mizuho, in a research note released last night, started ZIOPHARM with a buy rating and an $11 price target, implying 127% potential upside based on yesterday's close. Mizuho notes that ZIOPHARM's exclusive use of Intrexon's (NYSE:XON) RheoSwitch Therapeutic System for use in developing new oncology-based therapies could give it a unique advantage that may result in positive readouts this year. While ZIOPHARM's pipeline does offer promise, I remain cautious about that it only has two ongoing phase 2 clinical studies, and a number of preclinical studies. Until its pipeline becomes more mature, I'd prefer to stay on the sidelines.

Sinovac, Burlington, and ZIOPHARM all soared today, but even they could struggle to keep up with this top stock in 2014
There's a huge difference between a good stock and a stock that can make you rich. The Motley Fool's chief investment officer has selected his No. 1 stock for 2014, and it's one of those stocks that could make you rich. You can find out which stock it is in the special free report, "The Motley Fool's Top Stock for 2014." Just click here to access the report and find out the name of this under-the-radar company.

Sean Williams has no material interest in any companies mentioned in this article. You can follow him on CAPS under the screen name TMFUltraLong, track every pick he makes under the screen name TrackUltraLong, and check him out on Twitter, where he goes by the handle @TMFUltraLong.

The Motley Fool has no position in any companies mentioned in this article. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

A Financial Plan on an Index Card

Keeping it simple.

Aug 7, 2015 at 11:26AM

Two years ago, University of Chicago professor Harold Pollack wrote his entire financial plan on an index card.

It blew up. People loved the idea. Financial advice is often intentionally complicated. Obscurity lets advisors charge higher fees. But the most important parts are painfully simple. Here's how Pollack put it:

The card came out of chat I had regarding what I view as the financial industry's basic dilemma: The best investment advice fits on an index card. A commenter asked for the actual index card. Although I was originally speaking in metaphor, I grabbed a pen and one of my daughter's note cards, scribbled this out in maybe three minutes, snapped a picture with my iPhone, and the rest was history.

More advisors and investors caught onto the idea and started writing their own financial plans on a single index card.

I love the exercise, because it makes you think about what's important and forces you to be succinct.

So, here's my index-card financial plan:


Everything else is details. 

Something big just happened

I don't know about you, but I always pay attention when one of the best growth investors in the world gives me a stock tip. Motley Fool co-founder David Gardner (whose growth-stock newsletter was rated #1 in the world by The Wall Street Journal)* and his brother, Motley Fool CEO Tom Gardner, just revealed two brand new stock recommendations moments ago. Together, they've tripled the stock market's return over 12+ years. And while timing isn't everything, the history of Tom and David's stock picks shows that it pays to get in early on their ideas.

Click here to be among the first people to hear about David and Tom's newest stock recommendations.

*"Look Who's on Top Now" appeared in The Wall Street Journal which references Hulbert's rankings of the best performing stock picking newsletters over a 5-year period from 2008-2013.

Compare Brokers